Satellos Bioscience’s (MSLE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Satellos Bioscience (NASDAQ:MSLE) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the stock. HC Wainwright also issued estimates for Satellos Bioscience’s Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.92) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.51) EPS, FY2027 earnings at ($1.89) EPS, FY2028 earnings at ($1.88) EPS, FY2029 earnings at ($0.88) EPS and FY2030 earnings at $0.86 EPS.

Other equities research analysts also recently issued research reports about the company. Guggenheim assumed coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a report on Friday, August 7th. Finally, Wells Fargo & Company set a $18.00 price target on Satellos Bioscience in a research report on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.75.

Satellos Bioscience Stock Up 2.9%

Shares of Satellos Bioscience stock opened at $10.09 on Monday. The firm has a market cap of $210.28 million, a PE ratio of -5.25 and a beta of 1.51. Satellos Bioscience has a twelve month low of $4.91 and a twelve month high of $13.39. The business has a 50-day simple moving average of $8.44.

Satellos Bioscience (NASDAQ:MSLE) last announced its earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). On average, equities analysts forecast that Satellos Bioscience will post -2.08 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC boosted its holdings in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 491,624 shares of the company’s stock after purchasing an additional 391,624 shares during the period. Satellos Bioscience comprises approximately 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 2.36% of Satellos Bioscience worth $3,723,291,000 at the end of the most recent quarter.

Key Headlines Impacting Satellos Bioscience

Here are the key news stories impacting Satellos Bioscience this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and an $18 target price for Satellos Bioscience (MSLE), substantially above the stock’s recent trading level. The bullish rating may be supporting investor interest. Satellos Bioscience Earns Buy Rating from HC Wainwright
• Neutral Sentiment: The analyst continues to project a path toward profitability, forecasting positive EPS of $0.86 in fiscal 2030, although that estimate was reduced from $0.93.
• Negative Sentiment: HC Wainwright lowered EPS estimates across multiple periods, including Q3 and Q4 2026, all quarters of 2027, and fiscal years 2026–2029. The FY2026 forecast was reduced to a loss of $1.92 per share from $1.60, while FY2027 was cut to a loss of $1.89 from $1.76.
• Negative Sentiment: The revisions imply larger or more persistent losses than previously expected. They also come as the company’s current-year consensus forecast remains a loss of approximately $1.85 per share, which could limit upside if investors focus on cash needs and the timing of profitability.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.